Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.813 USD | -12.10% | -3.01% | +116.37% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
1.39M | - | - | - | - | - | |
56.87B | - | |||||
39.72B | ||||||
39.27B | ||||||
28.73B | ||||||
26.21B |
- Stock Market
- Equities
- LADX Stock
- Charts LadRx Corporation
- Sector Chart